The gold standard for facioscapulohumeral muscular dystrophy (FSHD) genetic diagnostic procedures was published in 2012. With the increasing complexity of the genetics of FSHD1 and 2, the increase of genetic testing centers, and the start of clinical trials for FSHD, it is crucial to provide an update on our knowledge of the genetic features of the FSHD loci and renew the international consensus on the molecular testing recommendations. To this end, members of the FSHD European Trial Network summarized the evidence presented during the 2022 ENMC meeting on Genetic diagnosis, clinical outcome measures, and biomarkers.
View Article and Find Full Text PDFJ Neurol Neurosurg Psychiatry
February 2024
Background: Amyotrophic lateral sclerosis (ALS) leads to paralysis and death by progressive degeneration of motor neurons. Recently, specific mutations in were identified in patients with juvenile form of ALS encodes the second catalytic subunit of the serine-palmitoyltransferase (SPT) complex.
Methods: We used the GENESIS platform to screen 700 ALS whole-genome and whole-exome data sets for variants in .
Background: The patients with neuromuscular diseases (NMD) are very fragile and it is hard to evaluate respiratory involvement of the primary disease in this group. Therefore, our study aimed to reveal the relationship between pulmonary function tests (PFT) and impulse oscillometry (IOS) and their correlation with respiratory clinical findings in NMD.
Material And Methods: A total of 86 consecutive patients with NMD were included.